文献速递膀胱癌与上尿路尿路上皮癌

疑似膀胱癌女性与男性 Medicare 受益人膀胱镜检率的地理差异

Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.
PubMed 文献 · Urology · 2018-08-20

该横断面研究分析了2014年306个医院转诊区全部按服务收费的 Medicare 受益人,计算年龄和种族调整后的膀胱镜检率。结果显示女性膀胱镜检率低于男性(每1000人平均11.0 vs 23.5,P < .001),但女性膀胱镜检率的变异系数更大(27.5 vs 23.5,P = .010),仅限血尿诊断码时结果一致。提示提供者对女性疑似膀胱癌的转诊和检查存在更大不确定性。

要点

  • 女性膀胱镜检率显著低于男性(每1000人平均11.0 vs 23.5,P < .001)。
  • 女性膀胱镜检率的变异系数大于男性(27.5 vs 23.5,P = .010)。
  • 仅限血尿诊断码时女性变异系数仍更大(27.8 vs 24.2,P = .022)。

核心结论

  • 女性膀胱镜检率低于男性,可能反映其膀胱癌发病率较低;但女性膀胱镜检率的变异更大,提示提供者对女性疑似膀胱癌的转诊和检查存在更大不确定性。

研究设计与样本

  • 横断面研究,纳入2014年306个医院转诊区(HRR)内全部按服务收费的 Medicare 受益人。
  • 主要结局为每个 HRR 中女性和男性年龄及种族调整后的膀胱镜检率(因膀胱癌症状行膀胱镜检的人数除以 HRR 内全部受益人)。

主要发现

  • 2014年共有173,551名女性(总人群14.8百万)和286,090名男性(总人群11.5百万)接受了膀胱镜检。
  • 女性膀胱镜检率低于男性(每1000人平均11.0 vs 23.5,P < .001)。
  • 女性膀胱镜检率的变异系数大于男性(27.5 vs 23.5,P = .010)。
  • 仅限血尿 ICD-9 诊断码时,女性变异系数仍大于男性(27.8 vs 24.2,P = .022)。
  • 在较大的 HRR 规模以及2010、2011、2012、2013年数据中,结果稳健。

临床怎么用

  • 临床医生应意识到女性疑似膀胱癌的膀胱镜检率存在更大地理差异,可能反映转诊和检查决策的不确定性。
  • 对于有膀胱癌症状的女性,需更规范地评估是否转诊和行膀胱镜检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess geographic variation in cystoscopy rates among women vs men with suspected bladder cancer, lending insight into gender-specific differences in cystoscopic evaluation. METHODS: We conducted a cross-sectional study of all fee-for-service Medicare beneficiaries within 306 Hospital Referral Regions (HRRs) who received care in 2014. For each HRR, we calculated the age- and race-adjusted cystoscopy rate for women and men as our primary outcome. The rate was the number of beneficiaries who underwent cystoscopy for bladder cancer symptoms (using procedure and ICD-9 diagnosis codes) divided by all beneficiaries in the HRR. We used the coefficient of variation to compare relative variability of cystoscopy rates. RESULTS: Overall, 173,551 women (n = 14.8 million) and 286,090 men (n = 11.5 million) underwent cystoscopy in 2014. While women received less cystoscopies compared to men (mean 11.0 vs 23.5 per 1000, P < .001), there was greater variation in cystoscopy rates among women (coefficient of variation 27.5 vs 23.5, P = .010). When restricting to ICD-9 codes for hematuria only, women continued to demonstrate greater variation in cystoscopy rates (coefficient of variation 27.8 vs 24.2, P = .022). Findings were robust across larger HRR sizes-thereby removing some random variation seen in smaller HRRs-as well as across years 2010, 2011, 2012, and 2013. CONCLUSION: Cystoscopy rates are lower in women than men, likely due to their lower bladder cancer incidence. However, there is greater variation in cystoscopy rates among women with symptoms of bladder cancer. This may reflect increased provider uncertainty whether to refer and work-up women with suspected bladder cancer.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Han DS, Zhou W, Seigne JD, et al. Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries. Urology. 2018. PMID: 30138684. doi:10.1016/j.urology.2018.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。